Recurrent Breast Cancer Completed Phase 2 Trials for Tipifarnib (DB04960)

Also known as: Breast Cancer Recurrent / Breast cancer NOS recurrent / Carcinoma breast recurrent / Breast carcinoma recurrent / Breast carcinoma NOS recurrent

IndicationStatusPhase
DBCOND0028640 (Recurrent Breast Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00082810Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast CancerTreatment
NCT00077363Capecitabine and Tipifarnib in Treating Women With Taxane-Resistant Metastatic Breast CancerTreatment